ModifiedBlue Cross Blue Shield of VermontPolicy 7.01.VT171

Remote Electrical Neuromodulation for Migraines (i.e., Nerivio®)

Customize your policy alerts

Sign up for bcbsvermont Policy 7.01.VT171 alerts

Get alerted when Policy 7.01.VT171 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage of FDA-approved remote electrical neuromodulation devices for acute treatment and prevention of migraine, including initial and continued use, investigational indications, contraindications, and eligible DME replacement.

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyRemote Electrical Neuromodulation for Migraines (i.e., Nerivio®)

Policy CodePolicy 7.01.VT171

Change TypeNew policy with added HCPCS A4540

Effective DateNov 1, 2026

Last ReviewJul 1, 2026

Next Review DateJul 1, 2027

Key ActionObtain prior approval for HCPCS A4540 when applicable policy criteria are met.

SourceLink

POLICY UPDATE CHANGES

The policy added HCPCS code A4540 for a distal transcutaneous electrical nerve stimulator that stimulates peripheral nerves of the upper arm.

A new policy was created with medical necessity criteria for remote electrical neuromodulation for treatment and prevention of migraine headache.

8+Minimum age for initial REN use

6 monthsRequired migraine history

6–24Preventive headache threshold

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedBlue Cross Blue Shield of VermontPolicy 7.01.VT171

Remote Electrical Neuromodulation for Migraines (i.e., Nerivio®)

Customize your policy alerts

Sign up for bcbsvermont Policy 7.01.VT171 alerts

Get alerted when Policy 7.01.VT171 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield of Vermont

PolicyRemote Electrical Neuromodulation for Migraines (i.e., Nerivio®)

Policy CodePolicy 7.01.VT171

Change TypeNew policy with added HCPCS A4540

Effective DateNov 1, 2026

Last ReviewJul 1, 2026

Next Review DateJul 1, 2027

Key ActionObtain prior approval for HCPCS A4540 when applicable policy criteria are met.

SourceLink

POLICY UPDATE CHANGES

The policy added HCPCS code A4540 for a distal transcutaneous electrical nerve stimulator that stimulates peripheral nerves of the upper arm.

A new policy was created with medical necessity criteria for remote electrical neuromodulation for treatment and prevention of migraine headache.

8+Minimum age for initial REN use

6 monthsRequired migraine history

6–24Preventive headache threshold

Medical Necessity and Coverage Criteria

Initial therapy

Initial use may be considered medically necessary when ALL four criteria are met.

Initial REN use

Age: The individual is 8 years of age or older.age >= 8 years
Migraine diagnosis and duration: The individual has a 6-month history of headaches meeting International Classification of Headache Disorders (ICHD 3-beta) diagnostic criteria for migraine with or without aura.headache history >= 6 months
Qualifying medication or clinical circumstance
- Medication response or tolerance: Insufficient response, contraindication, or intolerance to 2 or more guideline-recommended headache medications, such as anticonvulsants, antihypertensives, antidepressants, or CGRP inhibitors.2 or more medications
- Pregnancy or conception: The individual is pregnant, breastfeeding, or planning to conceive.
- Medication-overuse risk: The individual is at risk for or has a history of medication-overuse headache.
- Drug-interaction risk: The individual is at risk for drug-drug interactions with medications for comorbid conditions.
- Pediatric medication contraindication or intolerance: The child has a documented contraindication or intolerance to a medication.
Covered indication
- Acute treatment: REN is used to treat acute migraines.
- Prevention: REN is used to prevent migraine in an individual with 6 to 24 headache days per 28-day period in each of the 3 months preceding use of the REN device.6–24 headache days per 28-day period for each of 3 preceding months

Continuation therapy

Continued use may be considered medically necessary when BOTH criteria are demonstrated.

Continued REN use

Compliance: The individual is compliant with use of the REN device.
Clinical benefit: The individual demonstrates clinical benefit, such as fewer migraines or shorter duration of migraines.

Lost, stolen, or destroyed DME replacement

Replacement of lost, stolen, or destroyed DME may be covered when ALL criteria are met.

DME replacement

No alternative coverage: The item is not covered by an alternative entity, including homeowners or automobile insurance.
Health-risk consequence: Absence of the DME would put the member at risk of death, disability, or significant negative health consequences such as a hospital admission.
Warranty: The DME is still under warranty.

Non-FDA-approved remote electrical neuromodulation (REN) devices are considered investigational and are not covered under this policy.

REN use in individuals with contraindications is considered investigational. Contraindications include uncontrolled epilepsy and an active implantable medical device, such as a pacemaker, hearing-aid implant, or other implanted electronic device.

Trigeminal nerve stimulation devices, including Cefaly, are considered investigational for migraine treatment under this policy.

All other REN indications that do not meet the policy’s stated medical-necessity criteria are considered investigational.

Replacement of more than one lost, stolen, or destroyed durable medical equipment item, prosthetic, or orthotic per Plan Year is excluded. Replacement is also excluded when the applicable replacement criteria have not been met.

Covered Coding

Covered HCPCS CodesHCPCSCovered

A4540

Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm.

Authorization, Documentation, and Compliance

Prior Authorization

Prior Approval Required

Prior approval is required for HCPCS A4540 when applicable coverage criteria are met. Benefits remain subject to all terms, limitations, and conditions of the member’s subscriber contract.

HCPCS A4540: Distal transcutaneous electrical nerve stimulator that stimulates peripheral nerves of the upper arm.
Policy instructions: Prior Approval Required.

Documentation Required

Document Stolen Equipment

For replacement of stolen durable medical equipment, submit supporting documentation with the request, such as a police report.

Replacement is limited to one lost, stolen, or destroyed DME, prosthetic, or orthotic per Plan Year when the policy conditions are met.
The item must not be covered by an alternative entity, such as homeowners or automobile insurance.

Device and Treatment Background

Nerivio® is a wearable, nonpharmacologic device that delivers remote electrical neuromodulation (REN) by stimulating nerves in the upper arm. The device is controlled through a smartphone application and is recognized under this policy for the acute treatment and prevention of migraine.

Key Definitions

Headache day

DefinitionA calendar day with headache, regardless of severity or duration.

Preventive threshold6 to 24 headache days per 28-day period.

Measurement periodThe headache-day threshold applies in each of the 3 months preceding use of the REN device.

Remote electrical neuromodulation (REN)

DefinitionRemote electrical neuromodulation used to treat an acute migraine or prevent migraine.

Covered deviceAn FDA-approved device, such as Nerivio®.

Covered uses